Literature DB >> 30366935

Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis.

Constantinos O'Mahony1,2,3, Mohammed Majid Akhtar1,3,2, Zacharias Anastasiou4, Oliver P Guttmann1,3,2, Pieter A Vriesendorp5, Michelle Michels5, Damiano Magrì6, Camillo Autore6, Adrián Fernández7, Juan Pablo Ochoa7,8,9, Kevin M W Leong10, Amanda M Varnava10, Lorenzo Monserrat9,11, Aristides Anastasakis12, Pablo Garcia-Pavia3,13,14,15, Claudio Rapezzi16, Elena Biagini16, Juan Ramon Gimeno3,17, Giuseppe Limongelli3,18, Rumana Z Omar4, Perry M Elliott1,3,2.   

Abstract

OBJECTIVE: In 2014, the European Society of Cardiology (ESC) recommended the use of a novel risk prediction model (HCM Risk-SCD) to guide use of implantable cardioverter defibrillators (ICD) for the primary prevention of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). We sought to determine the performance of HCM Risk-SCD by conducting a systematic review and meta-analysis of articles reporting on the prevalence of SCD within 5 years of evaluation in low, intermediate and high-risk patients as defined by the 2014 guidelines (predicted risk <4%, 4%-<6% and ≥6%, respectively).
METHODS: The protocol was registered with PROSPERO (registration number: CRD42017064203). MEDLINE and manual searches for papers published from October 2014 to December 2017 were performed. Longitudinal, observational cohorts of unselected adult patients, without history of cardiac arrest were considered. The original HCM Risk-SCD development study was included a priori. Data were pooled using a random effects model.
RESULTS: Six (0.9%) out of 653 independent publications identified by the initial search were included. The calculated 5-year risk of SCD was reported in 7291 individuals (70% low, 15% intermediate; 15% high risk) with 184 (2.5%) SCD endpoints within 5 years of baseline evaluation. Most SCD endpoints (68%) occurred in patients with an estimated 5-year risk of ≥4% who formed 30% of the total study cohort. Using the random effects method, the pooled prevalence of SCD endpoints was 1.01% (95% CI 0.52 to 1.61) in low-risk patients, 2.43% (95% CI 1.23 to 3.92) in intermediate and 8.4% (95% CI 6.68 to 10.25) in high-risk patients.
CONCLUSIONS: This meta-analysis demonstrates that HCM Risk-SCD provides accurate risk estimations that can be used to guide ICD therapy in accordance with the 2014 ESC guidelines. REGISTRATION NUMBER: PROSPERO CRD42017064203;Pre-results. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  hypertrophic cardiomyopathy; implanted cardiac defibrillators; ventricular fibrillation

Mesh:

Year:  2018        PMID: 30366935     DOI: 10.1136/heartjnl-2018-313700

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  9 in total

Review 1.  Targeted Medical Therapies for Hypertrophic Cardiomyopathy.

Authors:  Carlo Fumagalli; Maria Grazia De Gregorio; Mattia Zampieri; Elisa Fedele; Alessia Tomberli; Chiara Chiriatti; Alberto Marchi; Iacopo Olivotto
Journal:  Curr Cardiol Rep       Date:  2020-01-28       Impact factor: 2.931

2.  Incremental Value of an Insertable Cardiac Monitor in Patients with Hypertrophic Cardiomyopathy with Low or Intermediate Risk for Sudden Cardiac Death.

Authors:  Rafi Sakhi; Roy Huurman; Dominic A M J Theuns; Arend F L Schinkel; Amira Assaf; Tamas Szili-Torok; Jolien W Roos-Hesselink; Michelle Michels; Sing-Chien Yap
Journal:  Cardiology       Date:  2021-01-21       Impact factor: 1.869

3.  ICD indication in hypertrophic cardiomyopathy: which algorithm to use?

Authors:  Marcelo Antônio Oliveira Santos-Veloso; Ândrea Virgínia Ferreira Chaves; Eveline Barros Calado; Manuel Markman; Lucas Soares Bezerra; Sandro Gonçalves de Lima; Brivaldo Markman Filho; Dinaldo Cavalcanti de Oliveira
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-08       Impact factor: 1.712

Review 4.  Contemporary Diagnosis and Management of Hypertrophic Cardiomyopathy: The Role of Echocardiography and Multimodality Imaging.

Authors:  Takeshi Kitai; Andrew Xanthopoulos; Shoko Nakagawa; Natsuko Ishii; Masashi Amano; Filippos Triposkiadis; Chisato Izumi
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-25

Review 5.  Promise and Peril of Population Genomics for the Development of Genome-First Approaches in Mendelian Cardiovascular Disease.

Authors:  Victoria N Parikh
Journal:  Circ Genom Precis Med       Date:  2021-02-01

6.  Age-related survival after alcohol septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  Angelika Batzner; Diaa Aicha; Barbara Pfeiffer; Anna Neugebauer; Hubert Seggewiss
Journal:  ESC Heart Fail       Date:  2021-12-13

7.  Identification of genes associated with sudden cardiac death: a network- and pathway-based approach.

Authors:  Jinhuan Wei; Xuejun Ni; Yanfei Dai; Xi Chen; Sujun Ding; Jingyin Bao; Lingyan Xing
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

Review 8.  Sleep Disordered Breathing in Hypertrophic Cardiomyopathy-Current State and Future Directions.

Authors:  Shreyas Venkataraman; Shahid Karim; Aiswarya Rajendran; C Anwar A Chahal; Virend K Somers
Journal:  J Clin Med       Date:  2020-03-25       Impact factor: 4.241

9.  A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy.

Authors:  Anastasia Miron; Myriam Lafreniere-Roula; Chun-Po Steve Fan; Katey R Armstrong; Andreea Dragulescu; Tanya Papaz; Cedric Manlhiot; Beth Kaufman; Ryan J Butts; Letizia Gardin; Elizabeth A Stephenson; Taylor S Howard; Pete F Aziz; Seshadri Balaji; Virginie Beauséjour Ladouceur; Lee N Benson; Steven D Colan; Justin Godown; Heather T Henderson; Jodie Ingles; Aamir Jeewa; John L Jefferies; Ashwin K Lal; Jacob Mathew; Emilie Jean-St-Michel; Michelle Michels; Stephanie J Nakano; Iacopo Olivotto; John J Parent; Alexandre C Pereira; Christopher Semsarian; Robert D Whitehill; Samuel G Wittekind; Mark W Russell; Jennifer Conway; Marc E Richmond; Chet Villa; Robert G Weintraub; Joseph W Rossano; Paul F Kantor; Carolyn Y Ho; Seema Mital
Journal:  Circulation       Date:  2020-05-18       Impact factor: 29.690

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.